Inventor · disambiguated record
Ian Sarvary
Also filed as: SARVARY IAN
9 granted patents·2 pending applications·11 citations·filing 2015–2023
80Inventor score
Top patents by PatentIndex Score
11 records- 0188US10689383B2Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseasesNUEVOLUTION AS·Filed 2015·Granted Jun 23, 2020·6 cites·59 claims
- 0284US11845760B2PRMT5 inhibitorsAMGEN INC·Filed 2021·Granted Dec 19, 2023·1 cites·46 claims
- 0384US10683293B2Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseasesNUEVOLUTION AS·Filed 2015·Granted Jun 16, 2020·3 cites·42 claims
- 0481US11254681B2Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseasesNUEVOLUTION AS·Filed 2020·Granted Feb 22, 2022·1 cites·54 claims
- 0575US12441704B2Compounds active towards nuclear receptorsNUEVOLUTION AS·Filed 2023·Granted Oct 14, 2025·0 cites·18 claims
- 0669US2024092794A1Novel prmt5 inhibitorsAMGEN INC·Filed 2023·Application pending·0 cites
- 0766US11685727B2Compounds active towards nuclear receptorsNUEVOLUTION AS·Filed 2020·Granted Jun 27, 2023·0 cites·16 claims
- 0854US11780843B2Compounds active towards nuclear receptorsNUEVOLUTION AS·Filed 2021·Granted Oct 10, 2023·0 cites·20 claims
- 0954US11613532B2Compounds active towards nuclear receptorsNUEVOLUTION AS·Filed 2021·Granted Mar 28, 2023·0 cites·21 claims
- 1052US11447479B2Compounds active towards nuclear receptorsNUEVOLUTION AS·Filed 2020·Granted Sep 20, 2022·0 cites·21 claims
- 1152US2023159510A1Novel prmt5 inhibitorsAMGEN INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ian Sarvary files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →